After 75 years of our alliance with the US, most Australians still can’t see a better option

The AgeIndependentProgressive2 hr. ago

Australia's largest pharmaceutical company, CSL, has signed agreements with the Trump administration to reduce medicine prices in the United States. This comes amid concerns over a 100% tariff imposed on Australian-made pharmaceuticals earlier in 2026. As part of the deal, CSL will offer discounted prices for its medicines under the US Medicaid program and agree to price-matching for new therapies. The agreements were made during a White House event where President Trump criticized pharmaceutical companies for exploiting US consumers. Nine global biotech firms, including CSL, have signed similar pricing agreements, with the goal of aligning US drug prices with those in other developed nations. The deals follow an executive order by Trump that imposed high tariffs on imported patented drugs but offered relief for companies moving production to the US. CSL also signed an 'onshoring agreement' to expand its plasma-therapies plant in Illinois.

Bias read (Progressive): The article frames the Trump administration's actions as efforts to address 'unfair drug pricing practices' and highlights the pressure on pharmaceutical companies to comply with US pricing policies. While the article presents facts neutrally, the emphasis on Trump's criticism of pharmaceutical prof

The Sydney Morning HeraldIndependentConservative2 hr. ago

CSL, Australia's largest pharmaceutical company, has signed agreements with the Trump administration to reduce medicine prices in the U.S. This comes in response to a 100% tariff imposed on Australian pharmaceuticals earlier in 2026. As part of the deal, CSL will offer discounted prices for its medicines under the U.S. Medicaid program and agree to price-matching for new therapies. The agreements were made during a White House event where President Trump criticized pharmaceutical companies for exploiting U.S. consumers. Nine global biotech firms, including CSL, have signed similar pricing agreements, with CSL also committing to expand its U.S. manufacturing operations. The deals follow an executive order that introduced tariffs but offered relief to companies moving production to the U.S.

Bias read (Conservative): The article frames the Trump administration's actions as a positive step toward reducing pharmaceutical costs and highlights the president's criticism of industry practices. The emphasis on the administration's efforts to secure commitments from major companies and the portrayal of Trump's rhetoric

The Conversation (AU)IndependentCenteryesterday

The article discusses the enduring nature of Australia's alliance with the United States despite recent tensions and criticisms. Signed in 1951, the ANZUS Treaty aimed to ensure mutual defense between Australia and the U.S. However, recent polling indicates growing doubts among Australians regarding the benefits of this alliance. Over the past 18 months, the U.S. has criticized its allies, including Australia, for 'freeloading' on security commitments and being 'very unhelpful' during conflicts involving Iran. Australia has faced trade sanctions, including a 12.5% tariff increase. Despite these challenges, only 15% of Australians currently support withdrawing from the alliance, down from 37% in 2023. Public confidence in the U.S. and trust in the alliance have declined significantly, especially under President Trump's second term. Australians are less certain about U.S. support in case of conflict with China and view China and the U.S. as equally helpful in Asia. While concerns about U.S. democracy persist, opinions have stabilized in 2026.

Bias read (Center): While the article presents a critical perspective on U.S.-Australia relations and highlights concerns about the alliance, it does not overtly favor one side over the other. It reports on both the criticisms from the U.S. and the continued support from Australians, presenting data from polls without傾